Catalyst Still Expecting Firdapse Approval in Canada in 2020
Despite the COVID-19 pandemic, Catalyst Pharmaceuticals is still expecting Firdapse (amifampridine) to be approved for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in Canada later this year, the company announced in an update. The company’s new drug submission (NDS) to Health Canada seeking approval…